Transparency
Market Research Reports included a detailed market survey and analysis trends
on “Epilepsy Therapeutics Market”.
This report also includes more info about basic overview of the industry including
definitions, applications and global market industry structure.
Epilepsy is a group of
long-term neurological disorders that is characterized by recurring seizures.
These seizures are episodes that occur when group of nerve cells or neurons in
brain sends wrong signals. Seizures could differ from primary generalized
seizures to partial seizures depending upon the cause of the epilepsy.
Patients suffering from epilepsy may complain about strange emotions and
sensations or they may behave strangely. Epilepsy is the fourth most common
brain disorder affecting people of all ages. For the treatment of epilepsy,
doctors prescribe antiepileptic medicines (AEDs) and the preference for the
drug depends on the type of seizures to be treated, age of the patient, part of
the brain involved and seriousness of the seizures.
Browse
Full Report with TOC: http://www.transparencymarketresearch.com/epilepsy-therapeutics-market.html
On the basis of the
available AEDs, epilepsy therapeutics market is segmented into two major
categories namely first generation AEDs and second generation AEDs. First
generation AEDs consist of following drugs:
- Carbamazepine (Carbatrol)
- Valproate (Depakote)
- Oxycarbazepine ((Trileptal)
- Phenytoin (Dilantin,
Phenytek)
- Ethosuximide (Zarontin)
- Phenobarbital (Luminal)
- Primidone (Mysoline)
- Topiramate (Topamax)
Second generation AEDs
consist of medicines with different mechanism of action than the first
generation drugs. This segment of epilepsy therapeutics market consists of
following drugs:
- Pregabalin (Lyrica)
- Lamotrigine (Lamictal)
- Levetiracetam (Keppra)
- Zonisamide (Zonegran)
- Lacosamide (Vimpat)
- Eslicarbazepine acetate
(Aptiom/Zebinix)
- Perampanel (Fycompa)
- Ezogabine/retigabine
(Trobalt/Potiga)
- Rufinamide (Banzel/Inovelon)
First generation AEDs
majorly carbamazepine, valproate, phenytoin and oxycarbazepine dominates the
epilepsy therapeutics market. However, second generation AEDs such as
levetiracetam, zonisamide and lacosamide are slowly overtaking the epilepsy
therapeutics market due to its improved efficacy and tolerability.
Additionally, large number of research and development activities, are going on
all over the world for the development of antiepileptic medicines with diverse
mechanism actions. As for instance two major players of epilepsy therapeutics
market namely UCB Pharma Ltd. and Marinus Pharmaceuticals, Inc. has developed
brivaracetam and ganaxolone respectively, for treating epilepsy. Both of these
drugs are currently under clinical trials and it is expected that these drugs
will prove beneficial for epilepsy therapeutics market.
North America leads the
epilepsy therapeutics market followed by Europe majorly due to the extensive
research and development activities and availability of second generation
drugs. Three new AEDs have been approved in U.S. since 2012 including
ezogabine/retigabine, perampanel and eslicarbazepine acetate and it expected
that brivaracetam will be approved soon.
Ezogabine/retigabine and perampanel
among these have novel mechanism of action and thus it is capturing good amount
of market share in U.S. Continuous increase in uptake of second generation AEDs
is also driving the epilepsy therapeutics market in North America and Europe.
Asia-Pacific is also increasing at faster pace for epilepsy therapeutics
market. High prevalence of epilepsy in India and China, increased penetration
due to better market access options in China and expected approval of drugs
with novel mechanisms are some of the factors responsible for expanding the
epilepsy therapeutics market in the Asia-Pacific region. Conversely, the
prescribing pattern of drugs that give preference to first generation AEDs over
second generation AEDs is restraining the epilepsy therapeutics market in this
region.
Some of the major
players in epilepsy therapeutics market include Abbott Laboratories,
GlaxoSmithKline plc, Cephalon, Inc., Johnson & Johnson, Pfizer, Inc.,
Novartis AG, Sunovion Pharmaceuticals, Inc.., Valeant Pharmaceuticals
International, Inc., Sanofi S.A. and Shire.
More Report on Pharmaceutical Market: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
This
research report analyzes this market depending on its market segments, major
geographies, and current market trends. Geographies analyzed under this
research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This report provides
comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming
years
This
report is a complete study of current trends in the market, industry growth
drivers, and restraints. It provides market projections for the coming years.
It includes analysis of recent developments in technology, Porter’s five force
model analysis and detailed profiles of top industry players. The report also
includes a review of micro and macro factors essential for the existing market
players and new entrants along with detailed value chain analysis.
Reasons for Buying this
Report
- This report provides pin-point
analysis for changing competitive dynamics
- It provides a forward looking perspective
on different factors driving or restraining market growth
- It provides a technological growth
map over time to understand the industry growth rate
- It provides a seven-year forecast
assessed on the basis of how the market is predicted to grow
·
It helps in making informed business
decisions by having complete insights of market and by making in-depth analysis
of market segments.
Download PDF: Global Epilepsy Therapeutics Market
About
Us:
Transparency Market
Research (TMR) is a market intelligence company providing global business
research reports and consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights for thousands
of decision-makers.
TMR’s experienced team
of analysts, researchers, and consultants use proprietary data sources along
with various tools and techniques to gather and analyze information. Our
business offerings represent the latest and the most reliable information which
is indispensable for businesses to sustain their competitive edge.
Our data repository is
continuously updated and revised by a team of research experts so that it
always reflects the latest trends and information.
Contact Us:
Sheela
AK
State
Tower,
90
State Street,
Suite
700,
Albany
NY – 12207
United
States
Tel:
+1-518-618-1030
Browse Market Research Report:-
0 comments:
Post a Comment